About Priothera
Priothera is a company based in Dublin (Ireland) founded in 2020 by Brice Suire and Florent Gros. Priothera has raised $35.47 million across 3 funding rounds from investors including European Investment Bank, Tekla Capital Management and Fountain Healthcare Partners. Priothera offers products and services including Mocravimod and CAR T Cell Therapy. Priothera operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, GigaGen, Kronos Bio and Carisma Therapeutics, among others.
- Headquarter Dublin, Ireland
- Founders Brice Suire, Florent Gros
- SectorsHealthcare
- Email••••••••
- Website priothera.com
- Social LinkedIn
- Legal Name Priothera Ltd
- Total Equity Funding$35.47M (USD)
in 3 rounds
- Latest Funding Round$1.96M (USD), Grant
Jun 2025
- InvestorsEuropean Investment Bank
& 4 more
Products & Services of Priothera
Priothera offers a comprehensive portfolio of products and services, including Mocravimod and CAR T Cell Therapy.
Immune modulator to enhance leukemia treatment outcomes.
Advances curative potential for blood cancer patients.
Funding Insights of Priothera
Priothera has successfully raised a total of $35.47M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.96 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.47M
- Total Rounds 3
- Last Round Grant — $1.96M
- First Round $35.47M
(Oct 2020)
- Investors Count 5
All 3 funding rounds of Priothera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $1.96M | Grant | – | – | – |
| Feb 2022 | $19.82M | Debt – Conventional | – | – | |
| Oct 2020 | $35.47M | Series A | – | Fountain Healthcare Partners, Healthcap |
5 investors in total: 5 institutional.
Investors in Priothera
Priothera has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Tekla Capital Management and Fountain Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Risk capital is provided to life sciences entrepreneurs. | – | fh-partners.com | Dublin, Ireland | |
- | – | healthcap.eu | - | |
Earlybird is recognized as a venture capital investor focused on early-stage tech companies. | – | earlybird.com | Berlin, Germany | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States |
Investor details for Priothera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Priothera
15 people are tracked at Priothera (8 in leadership, 7 in board & advisors).
| Name | Role | Group |
|---|---|---|
Brice Suire | Co-Founder | Leadership |
Florent Gros | Co-Founder & CEO | Leadership |
Philippe Lievre | Chief Business Officer & Founder | Leadership |
Frédéric David | Head Technical Development | Leadership |
Malika Souquières | Head of Clinical Sciences & Operations | Leadership |
Daniel Ghali | European Head Of Medical Affairs | Leadership |
Dymphy Huntjens | Head Clinical Pharmacology And Pharmacometrics | Leadership |
Karen Von Graevenitz | Head of Regulatory Affairs | Leadership |
Lionel Carnot | Director | Board & advisors |
Dhaval Patel | Director | Board & advisors |
Marten Steen | Director | Board & advisors |
Henry Skinner | Director | Board & advisors |
Christoph Bucher | Head of Clinical Advisory Board & Founder | Board & advisors |
Simone Seiter | Head of Commercial & Scientific Advisory Board & Founder | Board & advisors |
Manus Rogan | Chair | Board & advisors |
Complete people profiles for Priothera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Priothera
3 dated milestones of Priothera across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Priothera is founded.
- Funding First funding round of $35.5M.
- Funding Latest funding round, Grant, of $2.0M.
Competitors of Priothera
Priothera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, GigaGen, Kronos Bio and Carisma Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| januxrx.com | 2017 | San Diego, United States | $181M | 59 | Immunotherapeutics for cancer treatment are developed to target solid tumors. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| kronosbio.com | 2017 | San Mateo, United States | $271.01M | 97 | Small molecule therapeutics for cancer treatment are developed. | |
| carismatx.com | 2016 | Philadelphia, United States | $3.85M | 54 | Chimeric antigen receptor macrophages are developed for cancer treatment. | |
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| asherbio.com | 2019 | San Francisco, United States | $218.49M | – | Developer of immunotherapies for the treatment of cancer and autoimmune diseases | |
| cuebiopharma.com | 2015 | Cambridge, United States | $10M | 51 | Cue Biopharma is focused on developing immunotherapy solutions. |
Detailed competitors of Priothera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Priothera
Complete news archive for Priothera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Priothera
10 companies that operate in the same segment as Priothera (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Priothera
Priothera was founded in 2020.
Priothera is headquartered in Dublin, Ireland.
Florent Gros is the current CEO of Priothera. They have also founded this company.
Priothera is a funded company, having raised a total of $35.47M across 3 funding rounds to date. The company's 1st funding round was a Series A of $35.47M, raised on Oct 2020.
Priothera was founded in 2020 and is based in Dublin, Ireland. Focus is placed on the biotechnology sector, where therapeutics for hematological malignancies are developed. Operations center on mocravimod, an S1P receptor modulator used as adjunctive immune therapy alongside allogeneic hematopoietic stem cell transplantation. This approach serves as post-remission treatment for acute myeloid leukemia patients. Co-founders include Brice Suire and Florent Gros, who leads as CEO.
Priothera's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
Priothera offers Mocravimod and CAR T Cell Therapy.
Priothera has 5 investors. Key investors include European Investment Bank, Tekla Capital Management, Fountain Healthcare Partners, Healthcap, and Earlybird.
Priothera operates through Priothera Ltd.